Company profile: Argenx
1.1 - Company Overview
Company description
- Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
Products and services
- ARGX-117: argenx architects a humanized sweeping antibody inhibiting C2 and downstream complement activation for severe IgM-driven autoimmune diseases, directly modulating complement cascades
- Efgartigimod: argenx engineers an investigational antibody fragment that targets the neonatal Fc receptor (FcRn) to address severe autoimmune diseases driven by pathogenic IgG autoantibodies
- Empasiprubart: argenx creates a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to prevent degradation and improve C2 clearance from the bloodstream
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Argenx
ImCheck Therapeutics
HQ: France
Website
- Description: Provider of immunomodulatory antibody therapies and discovery services targeting cancer and immune-related diseases, including BTN3A monoclonal antibodies that modulate γ9δ2/γ9Vδ2 T cells: ICT01 to activate against advanced solid tumors; ICT41 to activate for viral, bacterial, and parasitic infections; and ICT21 to antagonize dysfunctional activation in autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImCheck Therapeutics company profile →
MBrace Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology solutions, including MBRC-101, an antibody-drug conjugate targeting the EphA5 receptor for solid tumors such as breast and lung cancer; SPARTA, a proprietary platform to identify new cancer targets and accelerate ADC development; and a Phase 1/1b clinical trial of MBRC-101 evaluating safety, tolerability, and preliminary efficacy in advanced metastatic solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MBrace Therapeutics company profile →
Tetherex Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapeutics under development, including SelK2, a humanized monoclonal antibody targeting PSGL-1 for asthma and COPD, and SC-Ad6-1, a single-cycle adenovirus vector expressing the SARS-CoV-2 spike protein for intranasal or intramuscular administration to induce mucosal and systemic immunity against COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetherex Pharmaceuticals company profile →
SAB Biotherapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and platform technologies, including SAB-142 for modulating the immune over-response in Type 1 Diabetes; SAB-176, a fully human polyclonal antibody for treatment and post-exposure prophylaxis of pandemic and seasonal influenza in high-risk patients; the DiversitAb platform for producing fully human, multi-targeted immunoglobulins without donors; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SAB Biotherapeutics company profile →
Syntimmune
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology drug candidates for a wide range of autoimmune diseases, advancing differentiated therapies based on expertise in neonatal Fc receptor (FcRn) biology and its role in the pathogenesis of IgG-mediated conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syntimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Argenx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Argenx
2.2 - Growth funds investing in similar companies to Argenx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Argenx
4.2 - Public trading comparable groups for Argenx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →